Pancreatic Cancer Research

ResearcherUniversity of TorontoActive in the last 2 years

Kelvin Chan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2501-3057; OpenAlex author ID A5008282524. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1177/17588359261449094↗
  2. A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening. Co-author DOI 10.3390/curroncol32040225↗
  3. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based … Last author DOI 10.1016/j.clon.2023.02.008↗
  4. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. Last author DOI 10.1093/jncics/pkac047↗
  5. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. Last author DOI 10.1001/jamanetworkopen.2021.33388↗
  6. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Last author DOI 10.1002/cam4.2704↗
  7. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Co-author DOI 10.1002/cam4.2705↗
  8. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. Last author DOI 10.1016/j.critrevonc.2019.102817↗
  9. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Last author DOI 10.1016/j.jval.2016.11.002↗
  10. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. Last author DOI 10.3747/co.22.2592↗
  11. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0108749↗
  12. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Last author DOI 10.3747/co.20.1223↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Jonathon Raphael · 4 shared papers, 2021–2026 · strength 0.78
  2. Natalie G. Coburn · 3 shared papers, 2020–2026 · strength 0.61
  3. Wei Fang Dai · 5 shared papers, 2020–2023 · strength 0.61
  4. Michail N. Mavros · 1 shared paper, 2026 · strength 0.36
  5. Diedron Lewis · 1 shared paper, 2025 · strength 0.33
  6. William W. L. Wong · 1 shared paper, 2025 · strength 0.33
  7. James Biagi · 2 shared papers, 2020–2023 · strength 0.26
  8. Ambica Parmar · 2 shared papers, 2020–2022 · strength 0.24
  9. Yoo‐Joung Ko · 3 shared papers, 2014–2020 · strength 0.23
  10. Nicole Mittmann · 2 shared papers, 2020–2022 · strength 0.22
  11. Kelly Lien · 3 shared papers, 2014–2017 · strength 0.18
  12. Vanessa Sarah Arciero · 1 shared paper, 2022 · strength 0.13
  13. Doug Coyle · 2 shared papers, 2014–2017 · strength 0.12
  14. Vincent Channing Tam · 2 shared papers, 2013–2015 · strength 0.10
  15. Y.J. Ko · 2 shared papers, 2013–2015 · strength 0.10
  16. Erin Diane Kennedy · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.